Buy these 2 quality ASX 200 shares: broker

A woman sits at her computer with hand to mouth and a contemplative smile on her face although she is considering or thinking about information she is seeing on the screen.

A woman sits at her computer with hand to mouth and a contemplative smile on her face although she is considering or thinking about information she is seeing on the screen.

Volatility on the ASX share market can open up opportunities to buy some good businesses, according to the experts.

Leading broker Morgan Stanley rates some leading S&P/ASX 200 Index (ASX: XJO) shares as buys, with compelling upside.

Many businesses on the ASX have seen their share prices drop in recent days and weeks. While there is much fear in the market about the effects of inflation and interest rates, investors may also be able to find some long-term opportunities.

Brokers can give a helpful hint about which ASX 200 shares could be worth owning at these prices, so let’s look at two of the buy-rated picks.

Goodman Group (ASX: GMG)

Goodman is one of the largest property businesses on the ASX. It has a global portfolio of properties and projects in the industrial real estate sector.

Morgan Stanley currently rates it as a buy ( or ‘overweight’) with a price target of $25.98. That implies a potential rise of more than 40% over the next year. One of the key factors that the broker likes about Goodman is its growing rent, which has been increasing at a pleasing pace over the last several years.

As an example, in the company’s FY22 third-quarter update, Goodman revealed a 12-month rolling like-for-like net property income (NPI) growth of 3.7%. It also had a five-year weighted average lease expiry (WALE), giving the business income visibility.

Another thing that Morgan Stanley likes is the ASX 200 share’s property development pipeline. It said that the concentration of its workbook in desirable locations has allowed it to increase its development work in progress (WIP) to $13.4 billion. Completions for the nine months to 31 March 2022 were $4.7 billion, with $6 billion in total expected for FY22.

Sonic Healthcare Ltd (ASX: SHL)

Sonic Healthcare is a large pathology healthcare business. It has operations in a number of countries including Australia, the US, and Germany.

It’s currently rated as a buy (‘overweight’) by Morgan Stanley. The price target is $40, implying a possible rise of around 20%. The broker points to COVID-19 testing as a positive for earnings in FY22.

The company’s COVID-19 testing operations are expected to give FY22 earnings a boost, as they did in FY21. However, the broker is expecting Sonic’s earnings to return to a more normal level in FY23. With that in mind, the Sonic Healthcare share price is valued at 10 times FY22’s estimated earnings and 16 times FY23’s estimated earnings.

The company said within its FY22 half-year result release that it’s expecting a “sustainable level of COVID-19 testing into the future, including routine COVID testing, screening programs, variant testing, whole genome sequencing and antibody tests”.

However, Sonic’s base business revenue is also rising. HY22 base revenue was up 4.3% year on year and up 2.5% compared to HY20 (which was before COVID-19).

A bonus is that Morgan Stanley is expecting the company to keep increasing its dividend over the next couple of years, which matches Sonic’s ‘progressive dividend policy’.

The post Buy these 2 quality ASX 200 shares: broker appeared first on The Motley Fool Australia.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.* Scott just revealed what he believes could be the “five best ASX stocks” for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now

See The 5 Stocks
*Returns as of January 12th 2022

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Sonic Healthcare Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/7IVxG5W

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s